Optogenetic therapy enhances vision in patients with retinitis pigmentosa
A clinical study published on October 7, 2026, in the New England Journal of Medicine demonstrated that optogenetic therapy enhanced visual function in 10 patients with advanced retinitis pigmentosa. Using an AAV vector for gene therapy, surviving retinal ganglion cells were made light-sensitive, allowing patients to use specialized goggles. Significant improvements in light sensitivity were noted in seven patients, with six achieving meaningful gains in everyday tasks.
A clinical study published on October 7, 2026, in the New England Journal of Medicine suggests that optogenetic therapy may offer a path toward treating visual impairment in those with advanced retinitis pigmentosa. The trial involved ten patients who received an intravitreal injection of an adeno-associated virus (AAV) vector expressing ChrimsonR, which is a light-sensitive protein. This method is designed to make surviving retinal ganglion cells responsive to light once again. Following the procedure, patients wore specialized goggles that convert ambient light into the specific wavelengths these modified cells are able to detect.
The results showed that seven of the ten patients had an increase in light sensitivity, with improvements ranging from factors of 2.0 to 62.3. Six patients also saw gains in their visual capabilities that translated to daily activities; while wearing the goggles, they were better able to detect and locate objects or find their way through doorways. This study marks an advancement in ocular therapy, building on the foundational research recognized by the 2026 Nobel Prize in optogenetics.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Liam covers climate solutions and the people helping the planet heal.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
